Sodium-glucose cotransporter 2 inhibitors across cardio-reno-metabolic disease and body mass index: a meta-analysis of randomized controlled trials

Key Points

• This research aims to evaluate the effects of SGLT2 inhibitors on cardiovascular outcomes across various body mass indices.
• Conducted a meta-analysis of randomized controlled trials
• Included diverse cardiovascular and renal populations
• Analyzed outcomes related to cardiovascular death and hospitalization
• SGLT2 inhibitors significantly reduced cardiovascular death and heart failure hospitalization
• These benefits were observed across all body mass index categories
• Overall mortality was also reduced with SGLT2 inhibitors

Abstract